HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
Authors
Keywords
-
Journal
Protein & Cell
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-11
DOI
10.1007/s13238-020-00694-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
- (2019) Nirav N. Shah et al. Frontiers in Oncology
- Emerging epigenetic-modulating therapies in lymphoma
- (2019) David Sermer et al. Nature Reviews Clinical Oncology
- HDAC3 inhibition up-regulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy
- (2019) Siyu Deng et al. MOLECULAR CANCER THERAPEUTICS
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
- (2019) Jiali Cheng et al. Frontiers in Oncology
- Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly
- (2018) A. Betsch et al. BLOOD REVIEWS
- Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
- (2018) Haneen Shalabi et al. HAEMATOLOGICA
- Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.
- (2018) Marie de Charette et al. HAEMATOLOGICA
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
- (2018) Joana N.R. Dias et al. Oncotarget
- Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
- (2018) Haneen Shalabi et al. HAEMATOLOGICA
- Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.
- (2018) Marie de Charette et al. HAEMATOLOGICA
- Overcoming Resistance of Human Non-Hodgkin’s Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors
- (2018) Antoni Torres-Collado et al. Cancers
- The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
- (2018) Hui Zhou et al. BMC CANCER
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor immunotherapy—the potential of epigenetic drugs to overcome resistance
- (2018) Camilla M. Grunewald et al. Translational Cancer Research
- B cell lymphomas present immunoglobulin neoantigens
- (2018) Michael S. Khodadoust et al. BLOOD
- Modulation of antitumor immunity with histone deacetylase inhibitors
- (2017) Tyler R McCaw et al. Immunotherapy
- PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
- (2017) Michal Šmahel INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens
- (2017) Michael S. Khodadoust et al. NATURE
- Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice
- (2017) Yaya Chu et al. OncoImmunology
- HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
- (2017) Marcel Nijland et al. OncoImmunology
- T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells
- (2016) I. Azzaoui et al. BLOOD
- Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma
- (2016) S. E. Assouline et al. BLOOD
- Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma
- (2016) Irina V. Tiper et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The urgent need to recover MHC class I in cancers for effective immunotherapy
- (2016) Federico Garrido et al. CURRENT OPINION IN IMMUNOLOGY
- Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice
- (2016) Veronica S. Gil et al. Disease Models & Mechanisms
- Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
- (2016) Marie de Charette et al. EUROPEAN JOURNAL OF CANCER
- HDAC5 controls the functions of Foxp3+ T-regulatory and CD8+ T cells
- (2016) Haiyan Xiao et al. INTERNATIONAL JOURNAL OF CANCER
- Combined deletion of Xrcc4 and Trp53 in mouse germinal center B cells leads to novel B cell lymphomas with clonal heterogeneity
- (2016) Zhangguo Chen et al. Journal of Hematology & Oncology
- CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
- (2016) Yanwen Jiang et al. Cancer Discovery
- Classical Hodgkin Lymphoma with Reduced 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
- (2016) M. G. M. Roemer et al. Cancer Immunology Research
- Effectively Targeting Burkitt Lymphoma By Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer Cells Combined with a Histone Deacetylase Inhibitor, Romidepsin in Vitro and In Humanized NSG Mice
- (2015) Yaya Chu et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents
- (2015) Sarah Frys et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
- (2015) R. Chen et al. HAEMATOLOGICA
- Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function
- (2015) Eva Sahakian et al. MOLECULAR IMMUNOLOGY
- Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
- (2015) K Cao et al. ONCOGENE
- A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
- (2015) R. Chen et al. HAEMATOLOGICA
- HDAC inhibitors and immunotherapy; a double edged sword?
- (2015) Michiel Kroesen et al. Oncotarget
- Expression of Histone Deacetylases in Diffuse Large B-cell Lymphoma and Its Clinical Significance
- (2014) Sung Hak Lee et al. International Journal of Medical Sciences
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Generation and repair of AID-initiated DNA lesions in B lymphocytes
- (2014) Zhangguo Chen et al. Frontiers of Medicine
- An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors
- (2013) A. C. West et al. CANCER RESEARCH
- Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma
- (2013) Kelly A. Cycon et al. IMMUNOLOGY
- Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer
- (2013) Je-In Youn et al. NATURE IMMUNOLOGY
- The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
- (2013) Jan M. Klein et al. PLoS One
- Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma
- (2012) P.-C. Tsai et al. CLINICAL CANCER RESEARCH
- Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
- (2012) Berkley E Gryder et al. Future Medicinal Chemistry
- The role of activation-induced deaminase in antibody diversification and genomic instability
- (2012) Jing H. Wang IMMUNOLOGIC RESEARCH
- Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma
- (2011) Madhavi Challa-Malladi et al. CANCER CELL
- Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
- (2011) K Ted Thurn et al. Future Oncology
- Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo
- (2011) Brian R. Rosborough et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Sirtuin-1 Targeting Promotes Foxp3+ T-Regulatory Cell Function and Prolongs Allograft Survival
- (2011) U. H. Beier et al. MOLECULAR AND CELLULAR BIOLOGY
- Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3+ T-Regulatory Cells
- (2011) E. F. de Zoeten et al. MOLECULAR AND CELLULAR BIOLOGY
- Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs
- (2010) Tatiana Akimova et al. CLINICAL IMMUNOLOGY
- Targeting histone deacetyalses in the treatment of B- and T-cell malignancies
- (2010) Jasmine Zain et al. INVESTIGATIONAL NEW DRUGS
- HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
- (2010) R Shimizu et al. LEUKEMIA
- Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
- (2009) J. Hiraga et al. BLOOD
- Mechanisms promoting translocations in editing and switching peripheral B cells
- (2009) Jing H. Wang et al. NATURE
- Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
- (2008) L. M. Rimsza et al. BLOOD
- Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
- (2008) N. A. Johnson et al. BLOOD
- Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells
- (2008) P. Serafini et al. CANCER RESEARCH
- Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching
- (2008) Jing H. Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Total Synthesis and Molecular Target of Largazole, a Histone Deacetylase Inhibitor
- (2008) Yongcheng Ying et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Structure and Activity of Largazole, a Potent Antiproliferative Agent from the Floridian Marine CyanobacteriumSymplocasp.
- (2008) Kanchan Taori et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started